Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Clin Endocrinol (Oxf) · 2006 · PMC1618957 · PMID 16918950

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

18 – 23 This also showed a trend to superiority on lan ATG, with 40% patients showing good biochemical control, rising from 35% on Lan MP.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.